Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy.
Bo Liu, Yao Bao, Jinan Ma, Xiaodong Wang, Yeqian Feng · Advances in radiation oncology · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont, no significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. No significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT.
What the Researchers Studied
The researchers studied participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 66.6% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 66.6% source-reported H₂ gas concentration; 3 L/min total gas flow (approximately 1998 mL/min H₂ component); via nasal cannula; H2HUBB estimated inhaled H₂ concentration: approximately 6.7–8.9% under standard resting adult assumptions from the source-reported 1.998 L/min pure-H₂ flow; reported treatment duration: 2 hours. No significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT. The authors concluded that hydrogen inhalation is a safe and effective adjunctive therapy that significantly alleviates inflammation and mitigates clinical symptoms of ARE in patients with cervical cancer who are undergoing CCRT, without compromising antitumor treatment outcomes. Molecular hydrogen, as a novel antioxidant and anti-inflammatory agent, may alleviate treatment-related toxicity. Table 4 Response Evaluation Criteria in Solid Tumors (RECIST) scores at different radiation therapy (RT) days in experimental and control groups Table 4 RT period Experimental group (n = 28) Control group (n = 30) χ 2 value P value Complete response 20 (71.43%) 24 (80.00%) Partial response 5 (17.86%) 3 (10.00%) Stable disease 1 (3.57%) 0 (0.00%) Progressive disease 2 (7.14%) 3 (10.00%) Intergroup comparison 1.997.573 In summary, this study demonstrated that hydrogen inhalation therapy, when administered concurrently with CCRT, significantly attenuates radiation-induced inflammatory responses and intestinal injury in cervical cancer patients, without compromising antitumor efficacy.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. The reported sample size was 26. The study used a randomized human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 66.6% source-reported H₂ gas concentration. H2HUBB estimated inhaled H₂ concentration: approximately 6.7–8.9% under standard resting adult assumptions from the source-reported 1.998 L/min pure-H₂ flow. This is a calculated estimate, not a directly measured concentration, and actual inhaled H₂ varies with breathing pattern, ventilation, cannula capture, and gas losses. The reported treatment duration was 2 hours.
Limitations and Safety
Reported limitations: The relatively small sample size and short follow-up duration may limit the generalizability of the results. Safety information: No adverse events related to hydrogen inhalation were reported. Hydrogen inhalation is a safe and effective adjunctive therapy that significantly alleviates inflammation and mitigates clinical symptoms of ARE in patients with cervical cancer who are undergoing CCRT, without compromising antitumor treatment outcomes.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.